the rns® system is an award-winning technology developed and manufactured in silicon valley that has been recognized for its innovation. similar to a pacemaker that monitors and responds to heart rhythms, the rns system is the world's first and only medical device that can monitor and respond to brain activity. neuropace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. the company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.in addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.
Company profile
Ticker
NPCE
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
223550230
NPCE stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
5 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
5 Mar 24
8-K
Departure of Directors or Certain Officers
7 Feb 24
8-K
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates
8 Jan 24
8-K
Entry into a Material Definitive Agreement
4 Dec 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
6 Nov 23
S-8
Registration of securities for employees
8 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
Transcripts
NPCE
Earnings call transcript
2023 Q4
5 Mar 24
NPCE
Earnings call transcript
2023 Q3
6 Nov 23
NPCE
Earnings call transcript
2023 Q2
8 Aug 23
NPCE
Earnings call transcript
2023 Q1
4 May 23
NPCE
Earnings call transcript
2022 Q4
2 Mar 23
NPCE
Earnings call transcript
2022 Q3
13 Nov 22
NPCE
Earnings call transcript
2022 Q2
13 Aug 22
NPCE
Earnings call transcript
2022 Q1
14 May 22
NPCE
Earnings call transcript
2021 Q4
10 Mar 22
NPCE
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
Change in insider ownership
18 Apr 24
4
Change in insider ownership
15 Apr 24
144
Notice of proposed sale of securities
15 Mar 24
4
Martha Morrell
28 Feb 24
4
Rebecca Kuhn
28 Feb 24
4
Joel Becker
28 Feb 24
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G/A
KCK LTD.
14 Feb 24
SC 13G/A
MORGAN STANLEY
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.84 mm | 9.84 mm | 9.84 mm | 9.84 mm | 9.84 mm | 9.84 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.98 mm | 2.67 mm | 767.33 k | 2.02 mm |
Cash used (since last report) | n/a | n/a | 13.18 mm | 17.71 mm | 5.10 mm | 13.40 mm |
Cash remaining | n/a | n/a | -3.34 mm | -7.87 mm | 4.74 mm | -3.56 mm |
Runway (months of cash) | n/a | n/a | -1.7 | -3.0 | 6.2 | -1.8 |
Institutional ownership, Q2 2023
93.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 24 |
Opened positions | 2 |
Closed positions | 4 |
Increased positions | 7 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 78.53 bn |
Total shares | 24.68 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
KCK | 5.62 mm | $25.24 bn |
Accelmed Partners II | 4.43 mm | $6.65 mm |
Orbimed Advisors | 4.01 mm | $18.02 bn |
Soleus Capital Management | 2.47 mm | $11.07 bn |
MS Morgan Stanley | 2.36 mm | $10.59 bn |
Soleus Private Equity Fund I | 1.78 mm | $0.00 |
FMR | 1.22 mm | $5.49 bn |
MDT Medtronic | 965.94 k | $9.74 mm |
Millennium Management | 628.93 k | $2.82 bn |
Nantahala Capital Management | 424.85 k | $1.91 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 14.06 | 2,623 | 36.88 k | 3,501,975 |
17 Apr 24 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 14.15 | 300 | 4.25 k | 3,504,598 |
16 Apr 24 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 14.01 | 14,069 | 197.11 k | 3,504,898 |
12 Apr 24 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 14.42 | 23,101 | 333.12 k | 3,518,967 |
11 Apr 24 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 14.49 | 461,899 | 6.69 mm | 3,542,068 |
27 Feb 24 | Rebecca Kuhn | Common Stock | Grant | Acquire A | No | No | 0 | 12,500 | 0.00 | 152,204 |
27 Feb 24 | Rebecca Kuhn | Stock Option Common Stock | Grant | Acquire A | No | No | 17.11 | 24,950 | 426.89 k | 24,950 |
27 Feb 24 | Becker Joel | Common Stock | Grant | Acquire A | No | No | 0 | 52,470 | 0.00 | 52,470 |
27 Feb 24 | Becker Joel | Stock Option Common Stock | Grant | Acquire A | No | No | 17.11 | 104,720 | 1.79 mm | 104,720 |
27 Feb 24 | Martha Morrell | Common Stock | Grant | Acquire A | No | No | 0 | 12,500 | 0.00 | 90,262 |
News
Wells Fargo Upgrades NeuroPace to Overweight, Raises Price Target to $20
14 Mar 24
The Latest Analyst Ratings For NeuroPace
12 Mar 24
JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $17
12 Mar 24
NeuroPace Provides Full-year 2024 Revenue Guidance Of $73M-$77M, Est $74.598M
5 Mar 24
Recap: NeuroPace Q4 Earnings
5 Mar 24